Terminal differentiation of embryonic progenitor cells to form distinct, adult tissues is the hallmark of organogenesis in complex organisms. However, in mammals including humans, this process is not readily reversible. Reversine is a 2,6-disubstituted purine derivative that was identified using a screening system based on the loss of terminal differentiation markers in C2C12 myoblast cells.1 Cultured myoblasts treated for four days with 5 µM reversine were dedifferentiated into confluent stem cell progenitors, that could then be induced by osteogenic or adipogenic medium to re-differentiate into bone or adipose precursors, respectively. Reversine is thus an important tool for the study of the control of cell fate.
1
Chen, S., Zhang, Q., Wu, X., et al. Dedifferentiation of lineage-committed cells by a small molecule. J Am Chem Soc126410-411(2004).